Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,356 recalls, newest first

Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Amerisource Health Services LLC NDC 68001-179-00 D-0759-2023
Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Amerisource Health Services LLC NDC 68001-178-00 D-0758-2023
Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Amerisource Health Services LLC NDC 68001-177-00 D-0757-2023
Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0431-90 D-0486-2023
Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0446-30 D-0485-2023
Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0688-30 D-0484-2023
Class II · Moderate risk

Simvastatin

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0710-90 D-0483-2023
Class II · Moderate risk

Glimepiride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0250-30 D-0482-2023
Class II · Moderate risk

Glimepiride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0488-30 D-0481-2023
Class II · Moderate risk

Glimepiride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0723-30 D-0480-2023
Class II · Moderate risk

Ropinirole

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 72189-0364-30 D-0479-2023
Class II · Moderate risk

Ropinirole

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 72189-0364-30 D-0478-2023
Class II · Moderate risk

Finasteride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0733-90 D-0477-2023

Recalls by year